Fenwick represents Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry, announced IP diligence...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here